• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

The New York Times – Business:

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Antitrust Laws and Competition Issues, Drugs (Pharmaceuticals), Humira (Drug), Intellectual Property, Inventions and Patents, Prices (Fares, Fees and Rates), Suits and Litigation (Civil)
←When Private Equity Came for the Toddler Gyms
How a Football Superfan in a Wolf Costume Ended Up in a Cage→

More posts

  • WATCH: Long security lines amid TSA staffing shortages, partial government shutdown

  • Small, 2.3 magnitude earthquake recorded near Sleepy Hollow, New York

  • Trump has questioned aides about Corey Lewandowski’s role in DHS ad campaign, sources say

  • Kellon Deryck And Ghostbond Launch Tone-Matching Wig Lace Adhesive

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube